Advertisement: Bradfield Centre mid
Barr Ellison Solicitors – commercial property
ARM Innovation Hub
RealVNC mid banner careers
Advertisement: Cambridge Network
Advertisement: Mogrify
Mid banner advertisement: BDO
Advertisement EY mid banner
RealVNC mid-banner general
Advertisement: RSM
Advertisement Cambridge China Centre
5 August, 2019 - 09:47 By Tony Quested

Sosei Heptares lines up potential $1.2bn from all-Japan alliance

Sosei Heptares, which is growing fast from Cambridge UK, has lined up a megabucks payout through a multi-target research, development and commercialisation partnership with Japanese life science technology compatriot Takeda. 

The collaboration combines Sosei Heptares’ GPCR-focused StaR® and structure-based drug design capabilities with Takeda’s discovery, development and therapeutic area expertise.

Sosei Heptares is eligible to receive up to $26 million in upfront and near-term payments in addition to research funding over the term of the agreement, plus future development, commercialisation and net sales-based milestone payments that may exceed $1.2 billion. 

The business is also eligible to receive tiered royalties on net sales of any licensed products by Takeda resulting from the partnership. 

Takeda receives exclusive global rights to develop and commercialise therapeutic agents for each novel target through specified pharmacological approaches in the collaboration.

The partnership will combine the proprietary GPCR-focused structure-based drug design capabilities at Sosei Heptares with Takeda’s extensive discovery, development and therapeutic area expertise directed towards multiple GPCR targets nominated by Takeda. 

The nominated targets represent new therapeutic intervention points across a range of diseases. The collaboration will initially focus on high-priority gastrointestinal targets, but the agreement includes the potential expansion into other therapeutic areas.

Dr Malcolm Weir, executive VP and chief R & D officer of Sosei Heptares, said: “Takeda and Sosei Heptares have enjoyed a strong relationship over the years, with its venture arm having been an early investor in Heptares. 

“This newly announced partnership is the culmination of recent discussions to identify new and exciting programs where our combined expertise can be directed towards challenging diseases and targets to deliver new medicines for patients.”

Shinichi Tamura, chairman, president and CEO of Sosei Heptares, added: “Sosei Heptares, like Takeda, has a proud heritage in Japan. This imbues both companies with a strong set of values and a powerful work ethic to create new medicines for patients in need around the world and in doing so build a successful, global company.”

Newsletter Subscription

Stay informed of the latest news and features